Financial reports
10-Q
2024 Q2
Quarterly report
8 Aug 24
ARS
2023 FY
Annual report to shareholders
16 May 24
10-Q
2024 Q1
Quarterly report
15 May 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
Current reports
8-K
CLN-978 is the first development stage CD19 T cell engager to receive U.S. FDA IND clearance in autoimmune diseases
16 Oct 24
8-K
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
17 Sep 24
8-K
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
8 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
27 Jun 24
8-K
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
3 Jun 24
8-K
Regulation FD Disclosure
23 May 24
8-K
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
15 May 24
8-K
Departure of Directors or Certain Officers
29 Apr 24
8-K
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
16 Apr 24
8-K
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
Registration and prospectus
424B3
Prospectus supplement
4 Jun 24
S-3
Shelf registration
16 May 24
S-8
Registration of securities for employees
14 Mar 24
S-3/A
Shelf registration (amended)
11 May 23
S-8
Registration of securities for employees
9 Mar 23
S-8
Registration of securities for employees
9 Mar 23
S-3
Shelf registration
9 Mar 23
S-8
Registration of securities for employees
10 Mar 22
424B4
Prospectus supplement with pricing info
11 Jan 21
S-1MEF
Registration of additional securities for an S-1
7 Jan 21
Proxies
DEFA14A
Additional proxy soliciting materials
16 May 24
DEF 14A
Definitive proxy
16 May 24
DEFA14A
Additional proxy soliciting materials
21 Apr 23
DEF 14A
Definitive proxy
21 Apr 23
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
Other
EFFECT
Notice of effectiveness
5 Jun 24
EFFECT
Notice of effectiveness
19 May 23
CORRESP
Correspondence with SEC
16 May 23
CORRESP
Correspondence with SEC
17 Mar 23
CORRESP
Correspondence with SEC
9 Mar 23
UPLOAD
Letter from SEC
9 Mar 23
EFFECT
Notice of effectiveness
8 Jan 21
CERT
Certification of approval for exchange listing
7 Jan 21
SEC STAFF
SEC staff action: Order
7 Jan 21
CORRESP
Correspondence with SEC
6 Jan 21
Ownership
SC 13G/A
VANGUARD GROUP INC
4 Nov 24
SC 13G
BlackRock, Inc.
22 Oct 24
4
Jennifer Michaelson
9 Sep 24
144
Notice of proposed sale of securities
5 Sep 24
3
Mary Thistle
9 Aug 24
4
Mary Thistle
9 Aug 24
4
Jennifer Michaelson
9 Jul 24
144
Notice of proposed sale of securities
5 Jul 24
4
Jennifer Michaelson
2 Jul 24
4
Stephen W Webster
27 Jun 24